13-May-2024
No headlines found.
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
Globe Newswire (Mon, 6-May 8:00 AM ET)
Amarin Reports First Quarter 2024 Business Update and Financial Results
Globe Newswire (Wed, 1-May 7:00 AM ET)
Globe Newswire (Wed, 24-Apr 2:00 PM ET)
Amarin Announces Results of Annual General Meeting of Shareholders
Globe Newswire (Mon, 22-Apr 8:00 AM ET)
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
Globe Newswire (Mon, 15-Apr 8:00 AM ET)
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
Globe Newswire (Mon, 8-Apr 8:00 AM ET)
Globe Newswire (Sat, 6-Apr 3:30 PM ET)
Amarin Provides Update on VAZKEPA (Icosapent Ethyl) Intellectual Property Portfolio in Europe
Globe Newswire (Wed, 3-Apr 8:00 AM ET)
Globe Newswire (Mon, 25-Mar 8:00 AM ET)
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Globe Newswire (Thu, 29-Feb 7:00 AM ET)
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
Amarin PLC - American Depositary Shares Each Representing One Ordinary Share trades on the NASDAQ stock market under the symbol AMRN.
As of May 13, 2024, AMRN stock price climbed to $0.92 with 1,023,783 million shares trading.
AMRN has a beta of 1.78, meaning it tends to be more sensitive to market movements. AMRN has a correlation of 0.11 to the broad based SPY ETF.
AMRN has a market cap of $375.07 million. This is considered a Small Cap stock.
Last quarter Amarin PLC - American Depositary Shares Each Representing One Ordinary Share reported $57 million in Revenue and -$.01 earnings per share. This fell short of revenue expectation by $-521,000 and exceeded earnings estimates by $.02.
In the last 3 years, AMRN stock traded as high as $5.97 and as low as $.65.
The top ETF exchange traded funds that AMRN belongs to (by Net Assets): SPDW, GWX, APIE, QQQS, BIB.
AMRN has underperformed the market in the last year with a return of -25.2%, while the SPY ETF gained +28.2%. In the last 3 month period, AMRN fell short of the market, returning -18.6%, while SPY returned +5.8%. However, in the most recent 2 weeks AMRN has outperformed the stock market by returning +4.9%, while SPY returned +2.1%.
AMRN support price is $.82 and resistance is $.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AMRN stock will trade within this expected range on the day.